Edition:
India

Ono Pharmaceutical Co Ltd (4528.T)

4528.T on Tokyo Stock Exchange

2,059JPY
6:05am IST
Change (% chg)

¥-4 (-0.19%)
Prev Close
¥2,063
Open
¥2,063
Day's High
¥2,078
Day's Low
¥2,055
Volume
213,700
Avg. Vol
1,536,844
52-wk High
¥3,430
52-wk Low
¥2,002

Latest Key Developments (Source: Significant Developments)

Vect-Horus Enters Into Collaboration And License Agreement With Ono Pharmaceutical Co Ltd
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>::VECT-HORUS ENTERS INTO COLLABORATION AND LICENSE AGREEMENT WITH ONO PHARMACEUTICAL CO., LTD..VECT-HORUS S.A.S. - VECT-HORUS WILL RECEIVE RESEARCH FEES, SUCCESS-BASED MILESTONES ON RESEARCH AND DEVELOPMENT PROGRESS.VECT-HORUS S.A.S. - VECT-HORUS WILL RECEIVE ROYALTIES ON SALES OF PRODUCTS..VECT-HORUS - ONO TO HAVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE ANY PHARMACEUTICAL PRODUCTS ARISING OUT OF DRUG DISCOVERY COLLABORATION.  Full Article

Ono Pharmaceutical says collaboration with Fate Therapeutics for two iPSC-derived CAR-T Therapies for Cancers
Tuesday, 18 Sep 2018 

Sept 18(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into a collaboration agreement with Fate Therapeutics Inc <<>>, for the joint development and commercialization of two off-the-shelf chimeric antigen receptor(CAR)-T cell product candidates for cancer.  Full Article

Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs .Under the terms of this agreement, BMS is granted the rights to develop and commercialize ONO-4578 and other compounds from PGE2 receptor antagonist programs worldwide, except Japan, South Korea, Taiwan, China and Association of South-East Asian Nations (ASEAN)countries.In accordance with this agreement, ONO receives an upfront payment of $40 million from BMS.ONO will also receive subsequent clinical, regulatory and sales-based milestone payments, as well as royalties based on sales of the products in the countries where ONO granted BMS the rights for development and commercialization.  Full Article

Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.BRISTOL-MYERS SQUIBB-WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING,COMMERCIALIZATION OF ONO-4578,OTHER PGE(2) RECEPTOR ANTAGONIST PRODUCTS.  Full Article

Ono Pharmaceutical completes retirement of treasury shares
Tuesday, 31 Oct 2017 

Oct 31(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it completed retirement of 45.9 million shares (7.8 percent of outstanding) on Oct. 31.Says the total shares outstanding 543.3 million shares after the retirement.  Full Article

Ono Pharmaceutical completes share repurchase
Monday, 2 Oct 2017 

Oct 2(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it completes repurchase of 15.9 million shares of its common stock, for 38.77 billion yen in total, from June 14 to Sept. 29.Share repurchase plan was announced on June 13.  Full Article

OncoTherapy Science says close of peptide vaccine related agreement with ONO PHARMACEUTICAL
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says peptide vaccine related agreement with.  Full Article

Ono Pharmaceutical to repurchase and retire shares
Tuesday, 13 Jun 2017 

June 13(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it will repurchase up to 20 million shares, representing 3.8 percent of outstanding.Says share repurchase price up to 50 billion yen in total.Says repurchase period from June 14 to Sept. 29.Says it will retire up to 50 million shares of its common stock, including repurchased shares between June 14 and Sept. 29, retirement date on Oct. 31.  Full Article

Ono Pharmaceutical concludes a license agreement with array biopharma related to MEK inhibitor and BRAF inhibitor
Wednesday, 31 May 2017 

May 31 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:* Says it concluded a license agreement with Array Biopharma Inc. to develop and commercialize binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, in Japan and.* Says Binimetinib and encorafenib are currently in two global Phase III trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study) and BRAF-mutant colorectal.* Under the terms of the agreement, ONO will pay to Array an upfront payment of 3.5 billion yen and milestones up to 17.3 billion yen and other expenses .  Full Article

Array Biopharma & Ono Pharmaceutical announce partnership for two Novel Oncology compounds
Wednesday, 31 May 2017 

May 31 (Reuters) - Array Biopharma Inc :Array Biopharma & Ono Pharmaceutical Co Ltd announce license, development & commercialization partnership for 2 Novel Oncology compounds, Binimetinib and Encorafenib.Array Biopharma says Array to receive $31.6 million up-front payment and up to $156.0 million in additional development and commercial milestones.Ono will receive rights to develop and commercialize Binimetinib and Encorafenib in Japan and South Korea.  Full Article